The French healthtech startup Alan has secured a significant funding round of €480m led by Prosus, valuing the company at €5.5bn. This latest investment follows just months after Alan announced a €100m funding round at a €5bn valuation, demonstrating the company's rapid growth and expansion in the European market.
What Happened
The new Series G funding round is being led by tech investing giant Prosus, alongside existing investors Teachers' Venture Growth (TVG) and Index Ventures, as well as new investor Dara Holdings. The investment will consist of both primary and secondary equity, with Prosus joining the round at a valuation of €5.5bn.
Alan's CEO and co-founder Jean-Charles Samuelian-Werve stated that this funding round will enable the company to "move faster" in its expansion plans, including entering new countries, deepening its presence in existing markets, and investing in AI healthcare services and product innovation.
Background and Context
Alan was founded in 2016 as a digital health insurance provider but has since expanded into a broader healthcare platform combining insurance, care, and prevention services. The company's AI-native approach allows it to offer more personalized healthcare experiences while scaling with limited headcount growth.
The company has reached over €800m in annual recurring revenue in the first quarter of 2026, representing 53% year-on-year growth. Alan serves over 1.1 million individuals and is profitable in France, its largest market.
Why It Matters to the Industry
The investment in Alan by Prosus highlights the growing interest in AI-driven healthcare solutions. The company's focus on prevention insurance, which combines health coverage, care navigation, wellbeing services, and AI-powered health assistance, is seen as a key area of growth in the industry.
Prosus' investment in Alan will also support the company's expansion into new international markets with strong Prosus presence. This partnership has the potential to unlock mutual benefits for both companies, including accelerating Alan's AI-led product development and driving its consumer offering.
What Comes Next
The €480m funding round is subject to regulatory approvals, which are expected to be completed in the coming months. Once approved, Alan will use the funds to accelerate its expansion plans, including entering new countries, deepening its presence in existing markets, and investing in AI healthcare services and product innovation.
Key Facts
- Alan has secured a €480m funding round led by Prosus, valuing the company at €5.5bn.
- The investment will consist of both primary and secondary equity.
- Prosus is joining the round alongside existing investors Teachers' Venture Growth (TVG) and Index Ventures, as well as new investor Dara Holdings.
- Alan has reached over €800m in annual recurring revenue in the first quarter of 2026, representing 53% year-on-year growth.
- The company serves over 1.1 million individuals and is profitable in France, its largest market.
The investment in Alan by Prosus highlights the growing interest in AI-driven healthcare solutions and the potential for prevention insurance to become a global standard. As the industry continues to evolve, it will be interesting to see how companies like Alan and Prosus work together to drive innovation and growth.
